Scientists scan tumors to unlock Next-Generation kidney cancer treatments
NCT ID NCT07179770
Summary
This early study aims to understand how the drug belzutifan affects a specific marker (CAIX) on kidney cancer tumors. Researchers will use special PET scans to measure changes in this marker before and after treatment in 12 patients with advanced kidney cancer that has progressed after prior immunotherapy. The information gathered will help design future combination treatments, but this study itself does not test whether those combinations work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.